After venetoclax, several direct inhibitors of IDH have been tested in clinical trials to antagonize 2-HG, but only two of them—enasidenib/AG-221 and ivosidenib/AG-120—have been approved for the treatment of refractory AML [70]. Here, IDH1 is linked to acute myeloid leukemia.